表紙
市場調査レポート

次世代生物製剤の世界市場 2016-2026年:治療用抗体技術・インスリン・成長ホルモン・遺伝子組換え血液凝固因子・再生医療

Next-Generation Biologics Market 2016-2026: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

発行 Visiongain Ltd 商品コード 298719
出版日 ページ情報 英文 275 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=133.97円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
次世代生物製剤の世界市場 2016-2026年:治療用抗体技術・インスリン・成長ホルモン・遺伝子組換え血液凝固因子・再生医療 Next-Generation Biologics Market 2016-2026: Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine
出版日: 2016年05月05日 ページ情報: 英文 275 Pages
概要

世界の次世代生物製剤市場規模は、2020年に213億米ドルに達すると予測されており、2026年まで収益は拡大を続ける見込みです。

当レポートでは、世界の次世代生物製剤市場について調査し、主要国市場の分析、次世代抗体・フラグメント・インスリンといった2次市場別の分析、再生医療市場の分析、および産業動向・今後の展望などを提供しております。

第1章 レポート概要

第2章 イントロダクション:次世代生物製剤

  • 生物製剤の発展の歴史
  • 次世代生物製剤の明るい見通し

第3章 世界の次世代生物製剤市場:展望・予測

  • 次世代生物製剤市場
  • 次世代生物製剤市場予測

第4章 主要国の次世代生物製剤市場

  • 主要国の次世代生物製剤市場
  • 主要市場における疾病発生率の上昇
  • 主要国市場における次世代生物製剤の承認
  • 米国は最大の次世代生物製剤市場となる
  • 日本における次世代生物製剤市場
  • 欧州における次世代生物製剤市場
  • 新興市場における次世代生物製剤市場

第5章 次世代抗体市場の展望

  • 抗体治療を改善する戦略
  • 次世代抗体治療市場
  • 次世代抗体治療市場予測
  • 抗体薬剤複合体(ADC)市場
  • 改変抗体市場
  • 二重特異性抗体市場

第6章 抗体フラグメントおよび新たな抗体様薬剤:商業的可能性

  • 次世代抗体フラグメント:ファブフラグメントを超えて
  • 抗体フラグメント・ALP市場予測
  • 次世代抗体フラグメントの展望
  • 抗体様タンパク質市場
  • 次世代免疫毒素の市場への影響

第7章 次世代インスリン市場:展望

  • 次世代インスリン開発の戦略
  • 次世代インスリン市場
  • 次世代インスリン市場予測
  • 経口インスリン市場
  • 超速攻型インスリン市場
  • 超持効型インスリン市場

第8章 次世代のその他の組み換えタンパク向け開発

  • 次世代のその他の組み換えタンパク市場の定義
  • 次世代組み換え凝固因子
  • 次世代の成長ホルモン

第9章 再生医療

  • 再生医療市場
  • 再生医療市場:収益予測
  • 幹細胞治療市場
  • ヒト組織工学の展望
  • 遺伝子治療市場

第10章 次世代生物製剤:産業動向

  • 次世代生物製剤:市場の強み
  • 次世代生物製剤:市場の弱み
  • 次世代生物製剤:STEP分析
  • 次世代生物製剤:開発動向
  • 次世代生物製剤製造の課題・機会
  • 次世代生物製剤の商業化
  • 次世代生物製剤開発のための提携

第11章 専門家へのインタビュー

第12章 結論

  • 次世代生物製剤市場は2026年まで力強い成長の見込み
  • 次世代抗体開発が市場をリードする見込み
  • 新たな治療法が次世代生物製剤の需要を促進する見込み
  • 次世代生物製剤の開発・商業化に残る課題

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0114

Emerging Biological Drugs - This New Study Reveals Selling Opportunities and Revenue Prospects to Help You Stay Ahead

What is the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your influence. And you explore trends, developments, results, opportunities and sales predictions.

Visiongain's new study reveals what is possible for biological drugs - their lucrative next phase. That survey helps you avoid missing out. Instead find developments in that industry and market, discovering expected progress and revenues. Discover where the money lies.

New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, seeing how high revenues can go.

Forecasting and other information showing the most promising opportunities for treatments

Our updated report gives sales forecasts to 2026 at overall world, submarket, product and national level. You see what the future holds, assessing gains for developers and producers.

Many opportunities exist. And besides giving revenue predictions, our analysis shows you recent results, growth rates and market shares. In that report you discover 127 tables, 47 charts and four interviews with companies. See, from 2016, what is possible.

In our study you get intelligence on competitors and their activities, especially products, deals and R&D. The following sections explain what that new investigation gives you.

Analyses exclusive to that study, showing the most important commercial potentials

In our report you get data found nowhere else. Discover what is happening and what is possible from 2016.

Our analysis benefits your plans, decisions and influence by interpreting medical needs, R&D and companies' technologies. There you hear what is happening, assessing opportunities and likely gains.

With those analyses you see where potential and money lie, also saving time and effort. That way you can also benefit your reputation for technological and commercial insight. The following sections explain how our study helps your work.

Prospects for that world market and submarkets - discover what is possible for next-generation biopharmaceuticals

In our report you see overall world sales to 2026 for those emerging biotherapies, exploring our discussions.

Also you gain individual revenue predictions to 2026 for six next-generation biologic submarkets at world level and their further subdivisions:

  • Next-generation antibody therapies, including the subsectors of antibody-drug conjugates (ADCs), engineered antibodies and bispecific treatments
  • Next-generation antibody fragments and antibody-like proteins (ALPs)
  • Next-generation insulins, including submarkets assessing oral insulins, ultra-long and ultra-rapid acting therapies
  • Next-generation recombinant coagulation factors
  • Next-generation growth hormones
  • Regenerative medicine, including tissue engineering, gene therapies and stem cells.

Our study also explores competition. There you see what is happening for developers, producers and sellers of new-generation biologics, understanding challenges, trends and outlooks. Explore what is possible.

That work also splits its overall world market into leading products, showing where you could profit from new and improved biotechnological medicines.

Product forecasts for new forms, variations and uses of biological therapy

How will individual drugs perform to 2026 at world level? Our report predicts revenues of eight top brands:

  • Kadcyla
  • Adcetris
  • Tresiba
  • Alprolix
  • Eloctate
  • Gazyva/Gazyvaro
  • Plegridy
  • Afrezza.

There you explore products and years with highest predicted sales. You also examine competitors. Hear what is happening, understanding challenges, trends, competition and opportunities.

For treating people and saving lives, you investigate progress, needs and possibilities. Discover how pharma companies satisfy those demands, also assessing expected financial gains from 2016.

Our work also shows you geographical revenue forecasts.

Demand in national markets - what outlooks for business in new biopharma products?

Advances in biotechnology and healthcare expand use of novel biological drugs in developed and developing countries. Many opportunities exist for new, improved treatments.

Our analyses show you individual revenue forecasts to 2026 for nine national markets:

  • United States
  • Japan
  • Germany, France, United Kingdom, Italy and Spain
  • China
  • India.

image1

There you hear about the best sales potentials, appraising national opportunities for next-generation biologics. See where revenues can rise, finding how you could gain.

And what events influence the biological drugs industry? What is the outlook for tackling serious diseases? Our work shows you, discussing trends, challenges and opportunities.

Market forces and issues - what affects biopharma developers, producers and sellers?

The report explains trends, processes and events affecting the follow-on biopharmaceuticals industry and market from 2016, including these forces:

  • Demands and needs for new biological therapies
  • Limitations of existing medicines
  • Promise of next-generation biologics and product launches
  • Extension of half-life - pegylation and other technologies
  • Contract manufacturers (CMOs) serving those developmental needs and trends.

And you explore these influences, among others:

  • Disease incidence and prevalence affecting demand for those new medicines
  • Improvements in therapeutic antibodies and variants, including targeted cytotoxic therapies
  • R&D pipelines - e.g. for immunotoxins - including agents in clinical development
  • Biosimilars and other follow-on protein agents transforming the biologics market
  • Effects of rising incidence rates in diabetes, cardiovascular disorders and cancer.

There discover what the future holds. That way you investigate political, economic, social and technological questions. And you find how R&D helps companies benefit patients.

With our study you explore what progress, trends and opportunities mean. And you discover what helps and hinders participants in the biomedical industry, affecting companies' results.

Biological drug technology and applications - companies and 2020 market value

What happens next? From 2016, novel follow-on treatments will benefit patients, healthcare providers and biomedical companies. Those advances will encourage investments, progress and higher revenues from more-advanced biological drugs. Discover what is possible.

Our study predicts the next-generation biologics market will reach $21.3bn worldwide in 2020, with strong revenue growth to 2026. See what the future holds for those products.

That work explores activities of these leading companies, among many other biopharmaceutical developers and producers:

  • Novo Nordisk
  • Eli Lilly
  • Bayer
  • Sanofi
  • Pfizer.

In that market large pharmaceutical corporations and smaller biopharma specialists can win. See how, exploring what is possible.

You also gain interviews with four companies - Ablynx, Crescendo Biologics, Sorrento Therapeutics and Affibody - helping you stay ahead in knowledge. Discover what is happening. See what organisations shaping that industry do, helping you succeed.

5 Ways Next-Generation Biologics Market 2016-2026 helps your analyses, plans and decisions

In these five main ways our new investigation helps you gain recognition for insight, benefiting your authority:

  • Revenues to 2026 at world level, for 17 market segments and 8 products - explore outlooks for R&D, production, marketing and sales
  • Forecasts to 2026 for 9 national markets in North America, Europe and Asia - assess countries for revenues and sales growth opportunities
  • Prospects for established competitors, rising companies and new entrants - investigate R&D, product portfolios, results and strategies
  • Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages
  • Interviews with 4 companies shaping that industry - discover what authorities say and do, helping you stay ahead in knowledge and succeed.

There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and prospects.

Trying our study now lets you discover biological drug trends, opportunities and forecasts

With our new report, by visiongain's UK-based in-house analysts, you discover analysis to help you stay ahead in knowledge. See there what the future holds for developers, producers and sellers of next-generation biomedicines. Find data you get nowhere else.

Our investigation is for everyone analysing biopharmaceuticals. There you discover data and forecasts for next-phase biopharmaceuticals. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.

Table of Contents

1. Report Overview

  • 1.1 Overview of the Next-Generation Biologics Market
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analytical Study
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Reports
  • 1.9 About Visiongain

2. Introduction to Next-Generation Biologics

  • 2.1 Brief History of Biological Drug Development
    • 2.1.1 Limitations of Present-Generation Biological Drugs
  • 2.2 The Promise of Next-Generation Biologics
    • 2.2.1 Defining Next-Generation Biologics
      • 2.2.1.1 A Definition of Regenerative Medicine
      • 2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies

3. World Next-Generation Biologics Market: Outlook and Forecast 2016-2026

  • 3.1 The Next-Generation Biologics Market 2015
    • 3.1.1 Development of the Next-Generation Biologics Market 2008-2015
    • 3.1.2 Rising Demand for Biological Therapies
    • 3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2015
    • 3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
    • 3.1.5 Leading Companies in the Next-Generation Biologics Market 2015
  • 3.2 The Next-Generation Biologics Market 2016-2026
    • 3.2.1 Growth Drivers for Biological Drug Revenues 2016-2026
    • 3.2.2 The Next-Generation Biologics Market Forecast 2016-2026
    • 3.2.3 Product Launches in All Sectors to Drive Market Growth 2016-2026
    • 3.2.4 Next-Generation Biologics: Market Restraints 2016-2026
    • 3.2.5 Rising Market Shares for Next-Generation Insulins 2016-2026

4. Leading National Submarkets for Next-Generation Biologics 2016-2026

  • 4.1 Leading National Submarkets for Next-Generation Biologics, 2015
    • 4.1.1 National Submarket Forecasts 2016-2026
    • 4.1.2 How Will National Submarket Shares Change to 2026?
  • 4.2 Rising Disease Incidence in Important Markets 2016-2026
  • 4.3 Approval of Next-Generation Biologics in Leading National Submarkets
  • 4.4 The US Will be the Largest Submarket for Next-Generation Biologics 2016-2026
    • 4.4.1 US Submarket Forecast 2016-2026
  • 4.5 Next-Generation Biologics in Japan 2016-2026
    • 4.5.1 National Expertise in Stem Cell Research
    • 4.5.2 Japanese Submarket Forecast 2016-2026
  • 4.6 Next-Generation Biologics in Leading EU Countries 2016-2026
    • 4.6.1 Regenerative Medicine Development in the EU
    • 4.6.2 Market Access for Next-Generation Biologics in the EU
    • 4.6.3 Germany: Submarket Forecast 2016-2026
    • 4.6.4 France: Submarket Forecast 2016-2026
    • 4.6.5 UK: Submarket Forecast 2016-2026
    • 4.6.6 Italy and Spain: Submarket Forecasts 2016-2026
  • 4.7 Next-Generation Biologics in Emerging Markets 2016-2026
    • 4.7.1 Next-Generation Biologics Development in Emerging Countries
    • 4.7.2 Chinese Submarket Forecast 2016-2026
    • 4.7.3 Indian Submarket Forecast 2016-2026

5. Next-Generation Antibodies: Submarket Outlooks 2016-2026

  • 5.1 Strategies for Improving Antibody Therapies
    • 5.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies
    • 5.1.2 Engineering Antibodies for Improved Potency
    • 5.1.3 Bispecific Antibodies
  • 5.2 Next-Generation Antibody Therapy Submarket
  • 5.3 Next-Generation Antibody Therapy Submarket 2016-2026
    • 5.3.1 Strong Revenue Growth for Next-Generation Antibodies 2016-2026
    • 5.3.2 Blockbuster Potential Will Drive Growth to 2026: Kadcyla, Adcetris and Cosentyx
    • 5.3.3 Next-Generation Antibodies: Submarket Restraints 2016-2026
  • 5.4 Antibody-Drug Conjugates (ADC) Submarket 2016-2026
    • 5.4.1 Antibody-Drug Conjugates Submarket Forecast 2016-2026
      • 5.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2016-2026
    • 5.4.2 What Will Drive Growth for ACDs to 2026?
    • 5.4.3 A Long Pipeline of ADCs in Clinical Development
      • 5.4.3.1 CMC544 (Pfizer): NHL Development Halted but Trials in ALL Continue
      • 5.4.3.2 NKTR-102 (Nektar Therapeutics): Phase III for Metastatic Breast Cancer
      • 5.4.3.3 CDX-011: Potential for Accelerated Approval in Breast Cancer
  • 5.5 Engineered Antibodies Submarket 2016-2026
    • 5.5.1 Engineered Antibodies Submarket Forecast 2016-2026
      • 5.5.1.1 Gazvya Will Lead the Submarket in 2026
    • 5.5.2 Portfolio Management to Drive Growth 2016-2026
    • 5.5.3 Engineered Antibodies Pipeline 2016
      • 5.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
  • 5.6 Bispecific Antibodies Submarket 2016-2026
    • 5.6.1 Bispecific Antibodies Submarket Forecast 2016-2026
    • 5.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2016-2026
    • 5.6.3 One New Approval and Two Phase II Bispecific Antibodies in 2016
      • 5.6.3.1 Blincyto (Amgen): The Second Approved Bispecific Antibody

6. Antibody Fragments and Novel Antibody-like Drugs: Commercial Potential 2016-2026

  • 6.1 Next-Generation Antibody Fragments: Beyond Fab Fragments
    • 6.1.1 Antibody-Like Proteins Mimic Antibody Therapies
    • 6.1.2 There are Advantages to Using Fragments and Novel Scaffolds
  • 6.2 Antibody Fragment and ALP Submarket 2016-2026
    • 6.2.1 Antibody Fragment and ALP Submarket Forecast 2016-2026
    • 6.2.2 Pharma is Investing Strongly in Antibody Fragments and ALPs
    • 6.2.3 Limited Late-Stage R&D Pipeline to Restrain Growth to 2026
  • 6.3 Outlook for Next-Generation Antibody Fragments 2016-2026
    • 6.3.1 Next-Generation Antibody Fragment Submarket Forecast 2016-2026
    • 6.3.2 One Platform Leads the Pipeline in 2016
      • 6.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis
      • 6.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication
  • 6.4 The Antibody-Like Protein Submarket 2016-2026
    • 6.4.1 Antibody-Like Protein Submarket Forecast 2016-2026
    • 6.4.2 Four ALPs in Clinical Development in 2016
      • 6.4.2.1 Abicipar Pegol (Allergan/Molecular Partners): Development of the Lead Clinical ALP Delayed
  • 6.5 Will Next-Generation Immunotoxins Change the Market to 2026?
    • 6.5.1 Challenges With First Generation Immunotoxins
    • 6.5.2 Fusion Protein Conjugates: Pipeline 2016
      • 6.5.2.1 Moxetumomab Pasudotox
    • 6.5.3 Humanised Immunotoxins
      • 6.5.3.1 Using Granzyme B in Immunotoxins
      • 6.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins

7. Next-Generation Insulin Submarket: Outlook 2016-2026

  • 7.1 Strategies for Next-Generation Insulin Development
    • 7.1.1 Reformulating Insulin for Convenient Administration
      • 7.1.1.1 Oral Insulin
      • 7.1.1.2 Inhaled Insulin
      • 7.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin
  • 7.2 Next-Generation Insulin Submarket 2016-2026
    • 7.2.1 Tresiba: Approved in the EU and Japan
      • 7.2.1.1 Tresiba: Revenue Forecast 2016-2026
  • 7.3 Next-Generation Insulin Submarket 2016-2026
    • 7.3.1 Next-Generation Insulin Submarket Forecast 2016-2026
    • 7.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2016-2026
    • 7.3.3 Next-Generation Insulin Submarket Restraints 2016-2026
      • 7.3.3.1 Biosimilar Insulins are Available Since 2015
  • 7.4 Oral Insulin Submarket 2016-2026
    • 7.4.1 Oral Insulin Submarket Forecast 2016-2026
    • 7.4.2 Oral Insulin: Submarket Drivers and Restraints 2016-2026
    • 7.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2016
      • 7.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II
      • 7.4.3.2 Oshadi Icp: Phase II Currently Recruiting
      • 7.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development
      • 7.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets
      • 7.4.3.5 Novo Nordisk: NN-1953
  • 7.5 Ultra-Rapid Acting Insulin Submarket 2016-2026
    • 7.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2016-2026
      • 7.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2026?
    • 7.5.2 Other Submarket Drivers and Restraints 2016-2026
    • 7.5.3 Ultra-Rapid Acting Insulin Pipeline 2016
      • 7.5.3.1 FlAsp (Novo Nordisk)
      • 7.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership
      • 7.5.3.3 Halozyme Therapeutics
      • 7.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates
      • 7.5.3.5 Afrezza: Inhaled Insulin Nearing the Market
      • 7.5.3.6 Adagio: A Second-Generation Inhaled Insulin
  • 7.6 Ultra-Long Acting Insulin Submarket 2016-2026
    • 7.6.1 Ultra-Long Acting Insulin Submarket Forecast 2016-2026
    • 7.6.2 Revenue Growth Driven by Uptake of Tresiba
    • 7.6.3 Ultra-Long Acting Insulin Pipeline 2016
      • 7.6.3.1 Toujeo: Sanofi's Next-Generation Insulin Analogue
      • 7.6.3.2 LY2605541 (Eli Lilly)
      • 7.6.3.3 LAPS-Insulin

8. Next-Generation Developments for Other Recombinant Proteins 2016-2026

  • 8.1 Defining Next-Generation for Other Recombinant Protein Sectors
    • 8.1.1 Next-Generation Interferon Beta: Plegridy Revenue Forecast 2016-2026
      • 8.1.1.1 Plegridy May Compete With Other Long-Acting Interferon Beta Therapies 2016-2026
    • 8.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise
      • 8.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2016
  • 8.2 Next-Generation Recombinant Coagulation Factors 2016-2026
    • 8.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2016-2026
    • 8.2.2 Submarket Drivers and Restraints 2016-2026
    • 8.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2016-2026
      • 8.2.3.1 Fused Factors: Biogen Idec's Eloctate and Alprolix
      • 8.2.3.2 Baxter's BAX 855
      • 8.2.3.3 CSL Behring's rlX-FP: Albumin-Bound Coagulation Factors
      • 8.2.3.4 Bayer's BAY94-9027
      • 8.2.3.5 Novo Nordisk's N8-GP for Haemophilia A
      • 8.2.3.6 Novo Nordisk's N9-GP for Haemophilia B
    • 8.2.4 Gene Therapy as a New Treatment Option for Haemophilia
  • 8.3 Next-Generation Growth Hormones 2016-2026
    • 8.3.1 Next-Generation Growth Hormone Submarket Forecast 2016-2026
    • 8.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormone 2016-2026
    • 8.3.3 Long-Acting Growth Hormones
      • 8.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone
      • 8.3.3.2 Prolor Biotech/OPKO Health
      • 8.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position
      • 8.3.3.4 Versartis: XTEN Technology for Half-Life Extension
    • 8.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients
      • 8.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin

9. Regenerative Medicine: Commercial Outlook 2016-2026

  • 9.1 The Regenerative Medicine Submarket in 2015
    • 9.1.1 Defining Regenerative Medicine
  • 9.2 The Regenerative Medicine Submarket: Revenue Projections 2016-2026
    • 9.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2016-2026
  • 9.3 The Stem Cell Therapies Submarket 2016-2026
    • 9.3.1 Prochymal (Mesoblast) for GvHD
      • 9.3.1.1 The Future for Prochymal: Approval in Crohn's Disease?
      • 9.3.1.2 A Note on Stem Cell Transplants
    • 9.3.2 Stem Cell Therapies Submarket Forecast 2016-2026
    • 9.3.3 Stem Cell Therapies: Submarket Drivers and Restraints 2016-2026
      • 9.3.3.1 Will iPSCs Prove Effective for Stem Cell Therapy?
    • 9.3.4 Stem Cell Therapies Late-Stage Pipeline 2016
      • 9.3.4.1 Cx601 (TiGenix)
      • 9.3.4.2 Mesoblast: Mesenchymal Stem Cell Therapies
      • 9.3.4.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate
      • 9.3.4.4 StemEx (Gamida Cell)
  • 9.4 Outlook for Tissue Engineering 2016-2026
    • 9.4.1 Two Sectors Lead the Market: Wound and Cartilage Repair
      • 9.4.1.1 Apligraf Leads the Wound Repair Submarket
      • 9.4.1.2 Organogenesis Markets Apligraf and Dermagraft from 2014
    • 9.4.2 Tissue Engineering Submarket Forecast 2016-2026
    • 9.4.3 Tissue Engineering: Submarket Drivers and Restraints 2016-2026
    • 9.4.4 Future Developments in Cartilage Repair: Pipeline 2016
    • 9.4.5 Organ Repair and Engineering: The Next Step in Tissue Engineering?
      • 9.4.5.1 Engineered Skin
      • 9.4.5.2 Engineered Veins
      • 9.4.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity
  • 9.5 The Gene Therapies Submarket 2016-2026
    • 9.5.1 Glybera Approved and Set for Launch in the EU
    • 9.5.2 Gene Therapies Submarket: Revenue Projections 2016-2026
    • 9.5.3 Glybera's Approval Driving Submarket Growth Since 2014
    • 9.5.4 There are More Than Five Gene Therapies in Late-Stage Development
      • 9.5.4.1 ProstAtak: Gene Therapy for Prostate Cancer
      • 9.5.4.2 TVEC (Amgen)
      • 9.5.4.3 Generx (Cardium Therapeutics)
      • 9.5.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy

10. Next-Generation Biologics: Industry Trends 2016-2026

  • 10.1 Next-Generation Biologics: Market Strengths 2016
  • 10.2 Next-Generation Biologics: Market Weakness 2016
  • 10.3 The Next-Generation Biologics Market: STEP Analysis 2016-2026
    • 10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
      • 10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes
      • 10.3.1.2 Next-Generation Biologic Development in Emerging Markets
    • 10.3.2 Technological Developments 2016-2026
    • 10.3.3 Economic Pressures 2016-2026
      • 10.3.3.1 High Drug Costs and Healthcare Spending
      • 10.3.3.2 Limited Commercial Potential in Emerging Markets?
    • 10.3.4 Political Issues: Regulatory Developments 2016-2026
  • 10.4 Next-Generation Biologics: Development Trends 2016-2026
    • 10.4.1 Improving Patient Convenience
    • 10.4.2 Sustained Release Biologics: Pegylation and Beyond
    • 10.4.3 Therapeutic Focus for Next-Generation Biologics
    • 10.4.4 Next-Generation Biologics as Personalised Medicine
  • 10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
    • 10.5.1 Contract Manufacturers Invest to Follow Development Trends
  • 10.6 Commercialising Next-Generation Biologics
    • 10.6.1 Product Lifecycle Management for First Generation Biologics
    • 10.6.2 Proving Benefit in Next-Generation Products
    • 10.6.3 Biosimilars as a Challenger 2016-2026
  • 10.7 Partnering for Next-Generation Biologic Development
    • 10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
    • 10.7.2 Most Development Platforms Stem from Small Biotechs

11. Research Interviews from Our Survey

  • 11.1 Dr Edwin Moses, CEO, Ablynx
    • 11.1.1 Ablynx
    • 11.1.2 Ablynx's Pipeline and Nanobody Technology
    • 11.1.3 On Caplacizumab
    • 11.1.4 Challenged with Current Biological Therapies
    • 11.1.5 The Next-Generation Biologics Market, 2016-2026
  • 11.2 Dr Mike Romanos, CEO, Crescendo Biologics
    • 11.2.1 Crescendo Biologics
    • 11.2.2 The Benefits in Antibody Fragment Therapies
    • 11.2.3 Treatment of Inflammation Indications with Antibody Fragments
    • 11.2.4 Crescendo's Fragment Pipeline
    • 11.2.5 Development and Production Platforms for Antibody Therapies
    • 11.2.6 Crescendo's Humabody ADCs and Multi-Specific T-Cell Engagers
    • 11.2.7 CB001, A Topical Biologic
    • 11.2.8 The Next-Generation Biologics Market, 2015-2025
  • 11.3 Sorrento Therapeutics Inc. Team: Dr Gunnar Kaufmann, VP of Research; Dr Kouros Motamed, VP, Strategic Alliances and Clinical Communications; George Uy, EVP and CCO
    • 11.3.1 Sorrento Therapeutics Inc.
    • 11.3.2 Sorrento's Pipeline
    • 11.3.3 Drivers and Restraints for Next-Generation Biologics
    • 11.3.4 The Next-Generation Biologics Market, 2015-2025
  • 11.4 Dr Fredrik Frejd, CSO, Affibody
    • 11.4.1 Affibody
    • 11.4.2 Challenges with Current Biological Therapies
      • 11.4.2.1 Current Half-Life Extension Technologies
    • 11.4.3 The Benefits of Affibodies Over Current Antibody Therapies
    • 11.4.4 Focus on Inflammation and Autoimmune Diseases
    • 11.4.5 Development of SOBI002
    • 11.4.6 Regulatory Challenges with Novel Biologics

12. Conclusions from Our Research and Analysis

  • 12.1 The Next-Generation Biologics Market Will Grow Strongly to 2026
  • 12.2 Next-Generation Antibody Development Will Lead the Market
  • 12.3 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
  • 12.4 Leading Regional Markets
  • 12.5 Challenges Remain in Developing and Commercialising Next-Generation Biologics

List of Tables

  • Table 2.1 First Approvals for Recombinant Protein Therapies, 1982-1997
  • Table 3.1 Top Ten Bestselling Prescription Pharmaceuticals: Revenues ($bn), 2015
  • Table 3.2 Next-Generation Biologics Market: Revenues by Sector ($bn), 2015
  • Table 3.3 Biological Drugs Market: Drivers and Restraints, 2016-2026
  • Table 3.4 Next-Generation Biologics Market: Overall Market Forecast and Revenue Forecasts ($bn) by Sector, 2015-2020
  • Table 3.5 Next-Generation Biologics Market: Overall Market Forecast and Revenue Forecasts ($bn) by Sector, 2021-2026
  • Table 3.6 Next-Generation Biologics: Market Shares (%) by Sector, 2015, 2020 and 2026
  • Table 4.1 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2015
  • Table 4.2 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2015-2020
  • Table 4.3 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2021-2026, Part 1
  • Table 4.4 Next-Generation Biologics Market: Revenues ($bn) by National Submarket, 2021-2026, Part 2
  • Table 4.5 Next-Generation Biologics: Market Shares (%) by National Submarket, 2020 and 2026
  • Table 4.6 National Incidence and Prevalence of Leading Indications Treated with Biologics (millions of patients), 2015
  • Table 4.7 Main Approval Dates for Next-Generation Biologics in Leading National Submarkets, 2003-2013
  • Table 4.8 US Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
  • Table 4.9 US Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
  • Table 4.10 Biosimilars Approved and Marketed in Japan, 2015
  • Table 4.11 Japanese Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
  • Table 4.12 Japanese Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
  • Table 4.13 Next-Generation Biologics Submarkets in the EU5 Nations: Revenues ($bn), 2015
  • Table 4.14 German Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
  • Table 4.15 German Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
  • Table 4.16 French Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
  • Table 4.17 French Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
  • Table 4.18 UK Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
  • Table 4.19 UK Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
  • Table 4.20 Italian Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
  • Table 4.21 Italian Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
  • Table 4.22 Spanish Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
  • Table 4.23 Spanish Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
  • Table 4.24 Chinese Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
  • Table 4.25 Chinese Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
  • Table 4.26 Indian Next-Generation Biologics Submarket Forecast ($bn), 2015-2020
  • Table 4.27 Indian Next-Generation Biologics Submarket Forecast ($bn), 2021-2026
  • Table 5.1 Monoclonal Antibodies Submarket: Leading Drug Revenues ($bn), 2015
  • Table 5.2 Next-Generation Antibodies Submarket: Approved Drug Revenues ($bn), 2015
  • Table 5.3 Selected Clinical and Pre-Clinical ADC Platforms, 2016
  • Table 5.4 Selected Clinical and Pre-Clinical Engineered Antibody Platforms, 2016
  • Table 5.5 Next-Generation Antibodies Submarket: Revenues by Sector ($bn), 2015
  • Table 5.6 Next-Generation Antibodies Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2015-2020
  • Table 5.7 Next-Generation Antibodies Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2021-2026
  • Table 5.8 Next-Generation Antibodies Submarket: Drivers and Restraints, 2016-2026
  • Table 5.9 Antibody Drug Conjugates Submarket: Revenues ($bn) and Submarket Shares (%) by Drug, 2015
  • Table 5.10 Antibody-Drug Conjugates Submarket Forecast ($bn), 2015-2020
  • Table 5.11 Antibody-Drug Conjugates Submarket Forecast ($bn), 2021-2026
  • Table 5.12 Kadcyla and Adcetris: Revenue Forecasts ($bn), 2015-2020
  • Table 5.13 Kadcyla and Adcetris: Revenue Forecasts ($bn), 2021-2026
  • Table 5.14 Antibody-Drug Conjugates Submarket: Drivers and Restraints, 2016-2026
  • Table 5.15 Selected Antibody-Drug Conjugates in Phase III Development, 2015
  • Table 5.16 Selected Antibody-Drug Conjugates in Phase II Development, 2015
  • Table 5.17 Selected Antibody-Drug Conjugates in Phase I Development, 2015
  • Table 5.18 Engineered Antibodies Submarket Forecast ($bn), 2015-2020
  • Table 5.19 Engineered Antibodies Submarket Forecast ($bn), 2021-2026
  • Table 5.20 Gazyva/Gazyvaro: Revenue Forecast ($bn), 2015-2020
  • Table 5.21 Gazyva/Gazyvaro: Revenue Forecast ($bn), 2021-2026
  • Table 5.22 Engineered Antibodies Submarket: Drivers and Restraints, 2016-2026
  • Table 5.23 Selected Engineered Antibodies in Phase II and III Development, 2016
  • Table 5.24 Bispecific Antibodies Submarket Forecast ($bn), 2015-2020
  • Table 5.25 Bispecific Antibodies Submarket Forecast ($bn), 2021-2026
  • Table 5.26 Bispecific Antibodies Submarket: Drivers and Restraints, 2021-2026
  • Table 5.27 Bispecific Antibodies in Phase I and II Development, 2015
  • Table 6.1 Selected Next-Generation Antibody Fragment Platforms, 2016
  • Table 6.2 Selected Antibody-Like Protein Platforms, 2016
  • Table 6.3 Next-Generation Antibody Fragment and ALP Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2015-2020
  • Table 6.4 Next-Generation Antibody Fragment and ALP Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2021-2026
  • Table 6.5 Next-Generation Antibody Fragment and ALP Submarket: Drivers and Restraints, 2016-2026
  • Table 6.6 Next-Generation Antibody Fragment Submarket Forecast ($bn), 2015-2020
  • Table 6.7 Next-Generation Antibody Fragment Submarket Forecast ($bn), 2021-2026
  • Table 6.8 Next-Generation Antibody Fragment Submarket: Clinical Pipeline, 2016
  • Table 6.9 Next-Generation Antibody-Like Protein Submarket Forecast ($bn), 2015-2020
  • Table 6.10 Next-Generation Antibody-Like Protein Submarket Forecast ($bn), 2021-2026
  • Table 6.11 Next-Generation Antibody-Like Protein Submarket: Clinical Pipeline, 2016
  • Table 7.1 Tresiba: Revenue Forecast ($bn), 2015-2020
  • Table 7.2 Tresiba: Revenue Forecast ($bn), 2021-2026
  • Table 7.3 Next-Generation Insulin Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2015-2020
  • Table 7.4 Next-Generation Insulin Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2021-2026
  • Table 7.5 Next-Generation Insulin Submarket: Drivers and Restraints, 2016-2026
  • Table 7.6 Diabetes: Prevalence and Proportion of Population Affected, 2015
  • Table 7.7 Leading Insulin Analogues: US and EU Patent Expiries, 2013-2018
  • Table 7.8 Oral Insulin Submarket Forecast ($bn), 2015-2020
  • Table 7.9 Oral Insulin Submarket Forecast ($bn), 2021-2026
  • Table 7.10 Oral Insulin Submarket: Drivers and Restraints, 2016-2026
  • Table 7.11 Oral Insulin: Selected Pre-Clinical and Clinical-Stage Pipeline, 2016
  • Table 7.12 Ultra-Rapid Acting Insulin Submarket Forecast ($bn), 2015-2020
  • Table 7.13 Ultra-Rapid Acting Insulin Submarket Forecast ($bn), 2021-2026
  • Table 7.14 Ultra-Rapid Acting Insulin Submarket: Drivers and Restraints, 2016-2026
  • Table 7.15 Ultra-Rapid Acting Insulin: Pre-Clinical and Clinical-Stage Pipeline, 2016
  • Table 7.16 Afrezza: Revenue Forecast ($bn), 2015-2020
  • Table 7.17 Afrezza: Revenue Forecast ($bn), 2021-2026
  • Table 7.18 Ultra-Long Acting Insulin Forecast ($bn), 2015-2020
  • Table 7.19 Ultra-Long Acting Insulin Forecast ($bn), 2021-2026
  • Table 7.20 Ultra-Long Acting Insulin Submarket: Drivers and Restraints, 2016-2026
  • Table 7.21 Selected Ultra-Long Acting Insulin: Clinical-Stage Pipeline, 2016
  • Table 8.1 Plegridy: Revenue Forecast ($bn), 2015-2020
  • Table 8.2 Plegridy: Revenue Forecast ($bn), 2021-2026
  • Table 8.3 Recombinant Coagulation Factor Half-Lives and Target Populations, 2015
  • Table 8.4 Next-Generation Recombinant Coagulation Factors Submarket Forecast ($bn), 2015-2020
  • Table 8.5 Next-Generation Recombinant Coagulation Factors Submarket Forecast ($bn), 2021-2026
  • Table 8.6 Next-Generation Recombinant Coagulation Factors Submarket: Drivers and Restraints, 2016-2026
  • Table 8.7 Long-Acting Recombinant Factors VIII and IX in Late-Stage Clinical Development, 2016
  • Table 8.8 Eloctate: Revenue Forecast ($bn), 2015-2020
  • Table 8.9 Eloctate: Revenue Forecast ($bn), 2021-2026
  • Table 8.10 Alprolix: Revenue Forecast ($bn), 2015-2020
  • Table 8.11 Alprolix: Revenue Forecast ($bn), 2021-2026
  • Table 8.12 Next-Generation Growth Hormones Submarket Forecast ($bn), 2015-2020
  • Table 8.13 Next-Generation Growth Hormones Submarket Forecast ($bn), 2021-2026
  • Table 8.14 Next-Generation Growth Hormones Submarket: Drivers and Restraints, 2016-2026
  • Table 8.15 Selected Next-Generation Growth Hormones in Clinical Development, 2016
  • Table 9.1 Regenerative Medicine Submarket: Revenues by Sector ($bn), 2015
  • Table 9.2 Regenerative Medicine Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2015-2020
  • Table 9.3 Regenerative Medicine Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2021-2026
  • Table 9.4 Regenerative Medicine Submarket: Drivers and Restraints, 2016-2026
  • Table 9.5 Stem Cell Therapies Submarket Forecast ($bn), 2015-2020
  • Table 9.6 Stem Cell Therapies Submarket Forecast ($bn), 2021-2026
  • Table 9.7 Stem Cell Therapies Submarket: Drivers and Restraints, 2016-2026
  • Table 9.8 Selected Stem Cell Therapies in Phase II and III Clinical Trials, 2016
  • Table 9.9 Selected Stem Cell Therapies in Phase I/II Development, 2016
  • Table 9.10 Tissue Engineering Submarket Forecast ($bn), 2015-2020
  • Table 9.11 Tissue Engineering Submarket Forecast ($bn), 2021-2026
  • Table 9.12 Tissue Engineering Submarket: Drivers and Restraints, 2016-2026
  • Table 9.13 Gene Therapies Submarket Forecast ($bn), 2015-2020
  • Table 9.14 Gene Therapies Submarket Forecast ($bn), 2021-2026
  • Table 9.15 Gene Therapies Submarket: Drivers and Restraints, 2016-2026
  • Table 9.16 Gene Therapies in Phase II and III Clinical Trials, 2016
  • Table 10.1 Next-Generation Biologics: STEP Analysis, 2016-2026
  • Table 10.2 Selected CMO Investments in Next-Generation Biologics, 2005-2015
  • Table 12.1 Next-Generation Biologics Market: Submarket Forecasts ($bn) and Market Shares (%), 2015, 2020 and 2026

List of Figures

  • Figure 1.1 Next-Generation Biologic Market Segmentation, 2016
  • Figure 3.1 Next-Generation Biologics: Market Shares (%) by Sector, 2015
  • Figure 3.2 Next-Generation Biologics Market: Revenue Forecast ($bn), 2015-2026
  • Figure 3.3 Next-Generation Biologics: Market Drivers, 2016-2026
  • Figure 3.4 Next-Generation Biologics: Market Restraints, 2016-2026
  • Figure 3.5 Next-Generation Biologics: Market Shares (%) by Sector, 2020
  • Figure 3.6 Next-Generation Biologics: Market Shares (%) by Sector, 2026
  • Figure 4.1 Next-Generation Biologics: Market Shares (%) by Country, 2015
  • Figure 4.2 Next-Generation Biologics: Market Shares (%) by Country, 2020
  • Figure 4.3 Next-Generation Biologics: Market Shares (%) by Country, 2026
  • Figure 4.4 US Next-Generation Biologics Submarket Forecast ($bn), 2015-2026
  • Figure 4.5 Japanese Next-Generation Biologics Submarket Forecast ($bn), 2015-2026
  • Figure 4.6 EU5 Nations: Next-Generation Biologics Submarket Shares (%), 2015
  • Figure 4.7 German Next-Generation Biologics Submarket Forecast ($bn), 2015-2026
  • Figure 4.8 French Next-Generation Biologics Submarket Forecast ($bn), 2015-2026
  • Figure 4.9 UK Next-Generation Biologics Submarket Forecast ($bn), 2015-2026
  • Figure 4.10 Italian Next-Generation Biologics Submarket Forecast ($bn), 2015-2026
  • Figure 4.11 Spanish Next-Generation Biologics Submarket Forecast ($bn), 2015-2026
  • Figure 4.12 Biosimilar Approvals in India, 2001-2015
  • Figure 4.13 Chinese Next-Generation Biologics Submarket Forecast ($bn), 2015-2026
  • Figure 4.14 Indian Next-Generation Biologics Submarket Forecast ($bn), 2015-2026
  • Figure 5.1 Next-Generation Antibodies: Submarket Shares (%) by Sector, 2015
  • Figure 5.2 Next-Generation Antibodies Submarket Forecast ($bn), 2015-2026
  • Figure 5.3 Antibody-Drug Conjugates: Submarket Shares (%) by Drug, 2015
  • Figure 5.4 Kadcyla and Adcetris: Revenue Forecasts ($bn), 2015-2026
  • Figure 5.5 Engineered Antibodies Submarket Forecast ($bn), 2015-2026
  • Figure 5.6 Bispecific Antibodies Submarket Forecast ($bn), 2015-2026
  • Figure 6.1 Next-Generation Antibody Fragment and ALP Submarket Forecast ($bn), 2015-2026
  • Figure 6.2 Next-Generation Antibody Fragment Submarket Forecast ($bn), 2015-2026
  • Figure 6.3 Next-Generation Antibody-Like Protein Submarket Forecast ($bn), 2015-2026
  • Figure 7.1 Tresiba: Revenue Forecast ($bn), 2015-2026
  • Figure 7.2 Next-Generation Insulin Submarket Revenue Forecast ($bn), 2015-2026
  • Figure 7.3 Diabetes: Proportion of Population Affected, 2015
  • Figure 7.4 Oral Insulin Submarket Forecast ($bn), 2015-2026
  • Figure 7.5 Ultra-Rapid Acting Insulin Submarket Forecast ($bn), 2015-2026
  • Figure 7.6 Afrezza: Revenue Forecast ($bn), 2015-2026
  • Figure 7.7 Ultra-Long Acting Insulin Submarket Forecast ($bn), 2015-2026
  • Figure 8.1 Plegridy: Revenue Forecast ($bn), 2015-2026
  • Figure 8.2 Next-Generation Recombinant Coagulation Factors Submarket Forecast ($bn), 2015-2026
  • Figure 8.3 Eloctate: Revenue Forecast ($bn), 2015-2026
  • Figure 8.4 Alprolix: Revenue Forecast ($bn), 2015-2026
  • Figure 8.5 Next-Generation Growth Hormones Submarket Forecast ($bn), 2015-2026
  • Figure 9.1 Regenerative Medicine: Submarket Shares (%) by Sector, 2015
  • Figure 9.2 Regenerative Medicine Submarket Forecast ($bn), 2015-2026
  • Figure 9.3 Stem Cell Therapies Submarket Forecast ($bn), 2015-2026
  • Figure 9.4 Tissue Engineering Submarket Forecast ($bn), 2015-2026
  • Figure 9.5 Gene Therapies Submarket Forecast ($bn), 2015-2026
  • Figure 10.1 Big Pharma Partnering Opportunities for Next-Generation Biologics Development, 2016

Companies Listed

  • 3SBio
  • Aastrom Biosciences (now Vericel Corporation)
  • AbbVie
  • Abcam
  • Ablynx
  • ADC Therapeutics
  • Adnexus (part of Bristol-Myers Squibb)
  • Adocia
  • Advanced Cell Technology (now Ocata Therapeutics)
  • Advantagene
  • Affibody
  • Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM)
  • Agensys (now part of Astellas Pharma)
  • Alcon (part of Novartis)
  • Alexion Pharmaceuticals
  • Alfacell (now Tamir Biotechnology)
  • Alkermes
  • Allergan
  • Allozyne
  • Ambrx
  • Amgen
  • AMRI
  • AnGes
  • Applied Genetic Technologies (AGTC)
  • Ark Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Athersys
  • Avita Medical
  • Babraham Institute
  • Baxter International
  • Bayer Healthcare
  • Belrose Pharma
  • Benda Pharmaceutical
  • Biocad
  • BioCancell Therapeutics
  • Biocon
  • Biodel
  • Biogen Idec
  • Bioheart
  • BioMarin Pharmaceutical
  • Biopartners (part of Bioton)
  • Biotest Pharmaceuticals
  • Bioton
  • BioVex Group (part of Amgen)
  • BioWa (part of Kyowa Hakko Kirin)
  • bluebird bio
  • Boehringer Ingelheim
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • Capricor Therapeutics
  • Cardio3 BioSciences
  • Cardium Therapeutics
  • Catalent Pharma Solutions
  • Celgene
  • Celladon
  • CellCoTec
  • Celldex Therapeutics
  • Cellerant Therapeutics
  • Cellular Dynamics International (CDI)
  • Centers for Disease Prevention and Control (CDC) [US]
  • Cephalon (part of Teva)
  • CEPiA (part of Sanofi)
  • Ceregene
  • Chatham Therapeutics
  • Chiesi Farmaceutici
  • Children's Hospital of Philadelphia (CHOP)
  • China Food and Drug Administration (CFDA)
  • Chugai (part of Roche)
  • Civitas Therapeutics
  • Clayton Biotechnologies
  • Cold Genesys
  • Concortis
  • Covagen
  • Crescendo Biologics
  • Critical Pharmaceuticals
  • CSL Behring
  • CytoMedix
  • Cytori Therapeutics
  • Dance Biopharm
  • Delenex Therapeutics
  • Depuy Mitek (part of J&J)
  • Diabetology
  • Diasome Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Duke University
  • Duke University Hospital
  • Dyax
  • Eddingpharm
  • EGEN
  • Eisai
  • Elan Pharmaceuticals (now part of Perrigo Company)
  • Eli Lilly
  • EMA's Committee for Medicinal Products for Human Use (CHMP)
  • Emisphere
  • Enzon Pharmaceuticals
  • EnzymeRx
  • Epitomics (part of Abcam)
  • ESBATech (part of Novartis)
  • European Commission
  • European Medicines Agency (EMA)
  • Flamel Technologies
  • Food and Drug Administration (FDA) [US]
  • Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
  • Fuji Pharma
  • Fujifilm Diosynth Biotechnologies
  • Gamida Cell
  • Genentech (part of Roche)
  • Generex Biotechnology
  • Genmab
  • Genzyme (part of Sanofi)
  • Geron
  • GlycoExpress
  • Glycotope
  • GlaxoSmithKline (GSK)
  • Halozyme Therapeutics
  • Hanmi Pharmaceutical
  • Health Canada
  • Hikma Pharmaceuticals
  • Histogenics
  • Humacyte
  • Human Stem Cells Institute (HSCI)
  • Igenica
  • ImmunoGen
  • Immunomedics
  • Innovent Biologics
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
  • Integra LifeSciences
  • International Diabetes Federation (IDF)
  • Introgen Therapeutics
  • Johnson & Johnson (J&J)
  • Jain Foundation
  • JCR Pharmaceuticals
  • Juventas Therapeutics
  • Karolinska Institute
  • Kyowa Hakko Kirin
  • LG Life Sciences
  • LifeCell
  • Lonza
  • Loyola University
  • MacroGenics
  • MannKind
  • MedImmune (part of AstraZeneca)
  • Merck & Co.
  • Merck KGaA
  • Merck Serono
  • Merrimack Pharmaceuticals
  • Merrion Pharmaceuticals
  • Mersana Therapeutics
  • Mesoblast
  • Micromet (part of Amgen)
  • Millennium Pharmaceuticals
  • Ministry of Health, Labor and Welfare (MHLW) [Japan]
  • Mitsubishi Tanabe Pharma
  • Mochida Pharmaceutical
  • Molecular Partners
  • Moorfields Eye Hospital [UK]
  • MorphoSys
  • National Cancer Institute (NCI) [US]
  • National Health Service (NHS) [UK]
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [US]
  • Nektar Therapeutics
  • Neopharm Group
  • NeoStem
  • NeuralStem
  • Nippon Kayaku
  • Novartis
  • Novo Nordisk
  • Nuron Biotech
  • NuVasive
  • Ocata Therapeutics (formerly Advanced Cell Technology)
  • OncoSec Medical
  • OPKO Health
  • Oramed Pharmaceuticals
  • Organogenesis
  • Organovo
  • Orthofix
  • Osiris Therapeutics
  • PeriphaGen Holdings
  • Perrigo Company
  • Pfizer
  • Pieris
  • Piramal Group
  • Progenics Pharmaceuticals
  • Prolor Biotech (part of OPKO Health)
  • Rani Therapeutics
  • ratiopharm (part of Teva)
  • Redwood Bioscience
  • Regeneron Pharmaceuticals
  • Reliance Life Sciences
  • ReNeuron
  • RIKEN [Japan]
  • Roche
  • Roche Glycart (part of Roche)
  • Royal Institute of Technology [Sweden]
  • Russian Ministry of Healthcare (Minzdrav)
  • SAFC
  • Sandoz (part of Novartis)
  • Sanofi
  • Scottish Medicines Consortium (SMC)
  • Seattle Genetics
  • Shanghai Sunway Biotech
  • Shenzhen SiBiono GeneTech (part of Benda)
  • Shreya Life Sciences
  • SironRX Therapeutics
  • Skye Orthobiologics
  • Sorrento Therapeutics
  • Sotex PharmFirm
  • Spark Therapeutics
  • Spectrum Pharmaceuticals
  • Spirogen (part of AstraZeneca)
  • Stanford University
  • Stelis Biopharmaceuticals (part of Strides Arcolab)
  • StemCells
  • Stem CentRx
  • Stempeutics Research
  • Strativa Pharmaceuticals
  • Strides Arcolab
  • Sutro Biopharma
  • Swedish Orphan Biovitrum (Sobi)
  • Swiss Federal Institute of Technology
  • Symphogen
  • Synthon
  • Synthon Biopharmaceuticals BV (part of Synthon)
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries
  • Thermalin Diabetes
  • Tianjin International Joint Academy of Bio-medicine
  • TiGenix
  • TRION Pharma
  • UCB
  • UniQure
  • University of California, San Francisco (UCSF)
  • University of Chicago
  • University of Toronto
  • USV
  • VBL Therapeutics
  • Vericel Corporation
  • Versartis
  • viDA Therapeutics
  • Viventia Biotechnologies Inc
  • VX Pharma
  • World Bank Group
  • World Cancer Research Fund (WCRF)
  • World Health Organization (WHO)
  • Wyeth (part of Pfizer)
  • Xencor
  • Xeris Pharmaceuticals
  • Yale School of Medicine
  • Zydus Cadila
Back to Top